Table 4.
The characteristics of MS patients who experienced MS relapse after COVID-19 during the Omicron wave
| Variables | Number (%) | P-value | |
|---|---|---|---|
| Relapse | Non-relapse | ||
| Number | 13 | 63 | |
| Age (mean ± SD) | 37.07 ± 8.34 | 36.73 ± 8.59 | |
| Age > 50 | 1 (7.7%) | 2 (3.17%) | 0.894 |
| Age ≤ 50 | 12 (92.3%) | 61 (96.83%) | 0.446 |
| Sex | |||
| Female | 8 (61.54%) | 55 (87.3%) | 0.025 |
| Male | 5 (38.46%) | 8 (12.7%) | |
| Duration of MS(mean ± SD) | 8.61 ± 5.56 | 11.80 ± 7.44 | 0.149 |
| EDSS | 3.42 ± 1.95 | 2.32 ± 1.97 | 0.072 |
| Type of MS | |||
| CIS | 2 (15.38%) | 2 (3.17%) | 0.10 |
| RRMS | 10 (76.92%) | 45 (71.43%) | |
| PPMS | 0 | 0 | |
| SPMS | 1 (7.7%) | 16 (25.4%) | |
MS multiple sclerosis, CIS clinically isolated syndrome, RRMS relapse-remitting MS, SPMS secondary progressive MS, PPMS primary progressive MS, DMT disease-modifying treatment, INFβ interferon beta, IM intramuscular, SC subcutaneous